Results 61 to 70 of about 2,796 (165)

Emerging Immune‐Based Therapeutic Strategies in Hepatocellular Carcinoma

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide despite recent advances in systemic therapy. The introduction of immune checkpoint inhibitors has substantially expanded treatment options for advanced disease; however, durable responses are observed only in a subset of patients.
Janine Kah, Werner Dammermann, Stefan Lueth   +2 more
wiley   +1 more source

Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy [PDF]

Oncolytic virotherapy is a promising immunotherapy approach for cancer treatment, utilizing viruses to preferentially infect and eliminate cancer cells while stimulating immune responses.
Daemen, Toos; id_orcid, Bhatt, Darshak K; id_orcid   +1 more
core   +4 more sources

Measles virus causes immunogenic cell death in human melanoma [PDF]

, 2011
NoOncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma.
Russell, S, Selby, P., Hadac, E., Donnelly, Oliver G, Jennings, V., Errington-Mais, F., Melcher, Alan A, Hadac, Elizabeth, Bond, J, Melcher, A.A., Bond, Jacquelyn, Selby, P, Bond, J., Peach, H., Vile, Richard, Steele, L., Vile, R., Hadac, E, Donnelly, O.G., Russell, Stephen, Harrington, K.J., Harrington, K, Peach, Howard, Steele, Lynette, Melcher, AA, Errington-Mais, Fiona, Harrington, Kevin, Russell, S., Phillips, Roger M., Pandha, H.S., Selby, Peter, Errington-Mais, F, Jennings, V, Scott, K, Phillips, RM, Phillips, Roger M, Scott, K., Pandha, Hardev, Vile, R, Jennings, Victoria, Steele, L, Pandha, H, Scott, Karen, Donnelly, OG, Peach, H   +44 more
core   +1 more source

Optimization of CEST MRI Reporter Protein Design Using Cation‐Pi Networks

Chemistry – A European Journal, Volume 32, Issue 28, 25 July 2026.
A novel engineering approach can produce reporter proteins for cell and viral therapy tracking with unique magnetic resonance imaging (MRI) signatures, detectable with chemical exchange saturation transfer (CEST). We discover how cation‐π interactions between amino acid groups can help us fine‐tune magnetic resonance properties for noninvasive ...
David E. Korenchan, Ethan J. French, Emerenziana Runco, Chetan B. Dhakan, Jinwu Yan, Hiroshi Nakashima, Michael T. McMahon, Assaf A. Gilad, Christian T. Farrar   +8 more
wiley   +1 more source

Emerging role of Natural killer cells in oncolytic virotherapy [PDF]

, 2015
Rauf Bhat, Jean Rommelaere Division of Tumor Virology, German Cancer Research Center, Heidelberg, Germany Abstract: Natural killer (NK) cells constitute a subtype of lymphocytes that initiate innate immune responses against tumors and virus-infected ...
Bhat R, Rommelaere J
core  

Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis

Scientific Reports, 2021
Vaccination can prevent viral infections via virus-specific T cells, among other mechanisms. A goal of oncolytic virotherapy is replication of oncolytic viruses (OVs) in tumors, so pre-existing T cell immunity against an OV-encoded transgene would seem ...
Amanda W. K. AuYeung, Robert C. Mould, Ashley A. Stegelmeier, Jacob P. van Vloten, Khalil Karimi, J. Paul Woods, James J. Petrik, Geoffrey A. Wood, Byram W. Bridle   +8 more
doaj   +1 more source

Current landscape and perspective of oncolytic viruses and their combination therapies

Translational Oncology, 2022
Oncolytic virotherapy has become an important strategy in cancer immunotherapy. Oncolytic virus (OV) can reshape the tumor microenvironment (TME) through its replication-mediated oncolysis and transgene-produced anticancer effect, inducing an antitumor ...
Yinghan Su, Changqing Su, Lunxiu Qin
doaj   +1 more source

Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy

Advanced Science, Volume 13, Issue 40, 17 July 2026.
ZIFOA‐M is engineered by conjugating oncolytic adenovirus‐loaded ZIF‐8 nanoparticles onto macrophage surfaces via bioorthogonal chemistry. Upon tumor infiltration, the platform releases OA to downregulate CD47/CD24 on tumor cells, restoring macrophage phagocytosis.
Jilong Wang, Ning Lu, Zhuo Yan, Luyi Ye, Luyao Bai, Shanshan Yuan, Yuting Zhu, Yiru Xiong, Yongheng Bai, Yaping Chen, Junjie Deng   +10 more
wiley   +1 more source

Oncolytic virotherapy - analysis, design, models [PDF]

The deliberate use of viruses as oncolytic (cancer killing) agents has become evident since initial observations tracing back to the early 20th century. However, clinical use of therapeutic viruses requires them to be safe and effective.
Bhatt, Darshak; id_orcid, Bhatt, Darshak
core   +1 more source

Oncolytic Virotherapy for human malignant mesothelioma: recent advances [PDF]

, 2015
International audienceCancer virotherapy is an attractive alternative to conventional treatments because it offers a wide range of antitumor effects due to 1) the diversity of the oncolytic viruses that are now available and 2) their multifaceted ...
Tangy, Frédéric, Boisgerault, Nicolas, Cellerin, Laurent, Achard, Carole, Grégoire, Marc, Fonteneau, Jean-François   +5 more
core   +1 more source